Non-relapse mortality after Allo-SCT has significantly decreased over the last years. Nevertheless, relapse remains a major cause for post SCT mortality in patients with AML and high-risk myelodysplastic syndrome (MDS). In this retrospective single-center analysis, we have analyzed the treatment outcomes of 108 patients with AML or MDS, who relapsed after Allo-SCT. Seventy of these patients (65%) were treated with salvage therapies containing chemotherapy alone, allogeneic cell-based treatment or the combination of both. Thirty-eight patients (35%) received palliative treatment. Median OS after diagnosis of relapse was 130 days. Compared with patients who received chemotherapy alone, response to salvage therapy was significantly improved in patients treated with a combination of chemo-and allogeneic cell-based therapy (CR rate 57% vs 13%, P = 0.002). Among risk factors concerning pretreatment characteristics, disease status before first Allo-SCT, and details of transplantation, only the time interval from Allo-SCT to relapse was an independent predictor of response to salvage therapy and OS. These data confirmed that time to relapse after transplantation is an important prognostic factor. Up to now, only patients eligible for treatment regimens containing allogeneic cell-based interventions achieved relevant response rates.
INTRODUCTION
Allo-SCT is an established and potentially curative treatment option for patients with myeloid malignancies such as AML or high-risk myelodysplastic syndrome (MDS). 1, 2 The implementation of reduced-intensity conditioning regimens has led to a significant reduction of transplant-associated toxicity, resulting in an increased number of patients eligible for SCT, including those of older age and/or with comorbidities. 3, 4 Despite these recent developments and improvement of supportive care, relapse after Allo-SCT, occurring in 30-40% of patients with AML 5, 6 and 15-35% of patients with MDS, 7-9 remains a major cause of treatment failure after Allo-SCT for myeloid malignancies. The management of these patients constitutes a significant challenge and a standard treatment has not yet been established. 10 Therapeutic options are limited and largely depend on the patient's general condition at the time of relapse. 10 Patients not eligible for intensive treatment are usually offered best supportive care, a low or intermediate dose chemotherapy or treatment with new drugs within clinical trials, aiming to achieve disease control rather than a subsequent remission. [11] [12] [13] Patients who are suitable for intensive treatment are mainly offered chemotherapy, often combined with donor cell-based immunologic therapy, in particular, infusion of DLI, an allogeneic stem cell boost, or even a second Allo-SCT with or without donor change, in order to induce a more potent GVL effect. 14, 15 Despite these attempts, response and survival rates remain dismal in AML and high-risk MDS patients with relapse after Allo-SCT. Without active treatment, the median OS ranges between 3 and 4 months. 16, 17 Even with intensive chemotherapy only a minority of~20% of patients achieve a CR and reported OS rates after 2 years are usually below 20%. 18 The prognosis is particularly poor among patients with early relapse (o 6 months after Allo-SCT) and/or active disease at the time of first Allo-SCT. 18 The aim of our single-center cohort analysis was to describe treatment strategies, response and survival rates of patients with AML or high-risk MDS with hematologic relapse after Allo-SCT. Furthermore, we attempted to determine possible prognostic factors among pre-treatment characteristics, disease status before allogeneic transplantation, details of transplantation and salvage strategies after relapse, that influence treatment response and survival in these patients.
MATERIALS AND METHODS Patients
Between January 2000 and May 2013, 474 patients underwent Allo-SCT for AML or high-risk MDS at the University Hospital of Muenster. Written informed consent was obtained from each patient before transplantation. Patients with hematologic relapse of their original disease were considered for this retrospective analysis if they had at least one remission evaluation confirming a CR, according to the definition below, including a complete donor chimerism after their first allogeneic transplantation. As of June 2013, 108 patients (23%) met these criteria and were therefore included in the analysis. received a haploidentical graft, was treated with fludarabine, thiotepa and melphalan in combination with muromonab-CD3.
RIC consisted of fludarabine and 8 Gy TBI (n = 43), fludarabine and treosulfan (n = 4), fludarabine and melphalan (n = 3) or fludarabine and BU (n = 1).
Patients with active disease or high-risk AML at the time of first Allo-SCT received sequential conditioning regimens with combinations of fludarabine, cytarabine, amsacrine, CY and 4 Gy TBI (FLAMSA-RIC) 20 or high-dose melphalan, followed by fludarabine and TBI (8 Gy). 21 
Definitions
Cytogenetic and molecular genetic risk stratification was performed according to the ELN classification. 22 Seventeen patients with a normal karyotype and an unknown NPM1 and/or Flt3 mutation status were classified as intermediate-I.
CR was defined as previously described. 23 In addition, incomplete hematopoietic recovery (neutrophils o1000/μL and platelets o100 000/ μL), usually denoted as CRi and possibly caused by GVHD and/or impaired graft function, was also considered as CR. 23 At least one chimerism analysis with documented complete donor cell chimerism (⩾95%) was required for the definition of CR after first or second Allo-SCT.
Non-relapse mortality was defined by death without disease relapse or refractoriness and when used in connection with a percent estimation related to deaths observed/patient population of interest.
Treatment strategies for post-transplantation relapse
In our evaluation, relapse refers only to hematologic relapse. When relapse was diagnosed, immunosuppressive treatment was discontinued immediately, if still ongoing and no signs of GVHD were present.
The choice of salvage therapy was at the discretion of the treating physicians. Criteria that influenced the physicians' selection of salvage therapy included: the general condition of patients at the time of relapse, the availability of the previous or a new stem cell donor, and the patients' wishes.
Treatment of patients with relapse after Allo-SCT consisted of at least one of the following options: (I) best supportive care, (II) palliative chemotherapy (low-dose cytarabine, sorafenib, mitoxantrone, lenalidomide, 5-azacytidine, hydroxyurea, or investigational drugs either as mono or combination therapy), (III) intensive chemotherapy (high or intermediate dose cytarabine in combination with anthracyclines or anthracenediones, combination of ifosfamide, carboplatin and etoposide), (IV) chemotherapy (low-dose cytarabine or high-dose cytarabine alone or in combination with mitoxantrone) followed by transfusion of stem cells from the original donor shortly after application of chemotherapy, (V) conditioning treatment followed by a second Allo-SCT with or without donor change and with (predominantly high-dose cytarabine in combination with mitoxantrone) or without prior induction chemotherapy, (VI) chemotherapy followed by transfusion of DLIs or (VII) discontinuation of immunosuppressive treatment followed by DLIs.
Statistical analysis
Relative and absolute frequencies are reported as descriptive statistics. Durations (age, time between 1st SCT and relapse, follow-up) are described as median time and range. CR rates after SCT are reported. Continuous variables were dichotomized at the median value.
The Χ 2 -test was performed to test for differences in response rates of distinct salvage therapies and other covariables. Factors significantly associated with the response are considered as predictive factors. OS after relapse was calculated from the day of relapse after first Allo-SCT until death from any cause. Survival rates were estimated by Kaplan-Meier analysis. Log-rank tests were used for univariate analysis of potential risk factors and different salvage treatment strategies on OS after relapse. The probabilities of relapse and non-relapse-related mortality were calculated using cumulative incidence estimates to accommodate competing risks (mortality in this analysis refers to number of deaths per number of patients involved in the evaluation).
A Cox proportional hazard regression model with a likelihood-ratiobased backward elimination of variables was used for multivariate analysis. All covariates with a Po0.1 in univariate log-rank test were selected for the initial Cox model. In addition, we included factors that were also likely to influence OS after relapse such as age, disease status before first allogeneic transplantation and the genetic risk profile according to the ELN Chronic GVHD after first HSCT, no. Not considered for donor related risk factor analysis.
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classification at first diagnosis. Hazard ratios were estimated with 95% confidence intervals (CIs). A P-value o0.05 was considered to indicate statistically significant differences in all analyses. Statistical testing was performed using SPSS version 22 (IBM Germany) and R 3.0.1 (http://www.R-project.org).
RESULTS

Patient and relapse characteristics
Pretreatment characteristics, disease status before and details of the first Allo-SCT (conditioning regimen, donor type, stem cell source, immunosuppressive treatment, incidence and severity of GVHD) of the 108 patients with AML (n = 105) or MDS (n = 3) are shown in Table 1 . The median number of days between first Allo-SCT and hematologic relapse was 149 days (range 14-1918 days), separating our cohort in patients with early and late relapse.
Risk factors for early relapse after first Allo-SCT As it is known that the duration of relapse-free survival after Allo-SCT is associated with OS, we attempted to identify patient characteristics, predicting early relapse after Allo-SCT in our cohort. Patients carrying a NPM1 mutation (P = 0.005), without detectable Flt3-ITD mutation (P = 0.003), patients who needed two or fewer cycles of chemotherapy to reach a first CR (P = 0.049), patients who stayed in first CR for 4 months or longer (P o 0.0001) and patients in CR before the first Allo-SCT (P = 0.02) were at a significant lower risk for early relapse ( Table 2) .
Management of relapse
The numbers of treated patients, response rates, outcome and causes of death for all treatment options can be obtained from Table 3 . Outcome was particularly poor in the 33 patients with a time to relapse after first Allo-SCT of 100 days or less. Only five of them received a second allogeneic transplantation. The median OS of these patients was 152 days (95% CI; 56-246 days) and none of them were alive 1 year after relapse.
Response to salvage therapy and survival Median OS of all patients in our cohort was 130 days (95% CI; 90-170 days) (Figure 1 ). The remission rate was highest in patients receiving a second Allo-SCT (CR in 14/19 patients; CR rate 74%), compared with patients receiving chemotherapy followed by a stem cell boost (CR in 15/31 patients; CR-rate 48%), patients treated with chemotherapy in combination with DLI (CR in 1/3 patients; CR rate 33%) and patients treated with chemotherapy alone (CR in 2/16 patients; CR rate 13%). In contrast, the OS rates did not differ significantly between these patient cohorts. The probability to be alive 1 year after relapse was 34% (95% CI; 10-59%) for patients treated with chemotherapy alone, 29% (95% CI; 13-45%) for patients who received chemotherapy followed by stem cell boost, and 26% (95% CI; 6-46%) for patients who received a second Allo-SCT after chemotherapy. None of the patients treated with chemotherapy and DLI survived 1 year after the diagnosis of relapse. One patient with rapid tapering of immunosuppression followed by DLIs remained in CR for more than 1 year.
Thirty-three (47%) of the 70 patients that received an intensive salvage treatment achieved a CR. Seventeen of these patients (51.5%) developed a second relapse after a median relapse-free interval of 117 days (range 20-1798 days). Patients with refractory disease at the time of first Allo-SCT had a significantly higher risk to relapse after intensive salvage treatment for relapse after SCT compared with patients who were initially transplanted in CR (data not shown).
All patients treated with chemotherapy followed by DLI died with progressive/refractory AML or MDS. Progressive/refractory disease was also the main cause of death in the patient group with intensive chemotherapy alone (78.6%) and intensive chemotherapy followed by a stem cell boost (63%). The number of patients with relapsed/progressive disease was noticeably lower in patients treated with a second Allo-SCT (35.3%), but in return these patients died more frequently from infectious complications during treatment (52.9%) or GVHD (11.8%).
Considering the above-mentioned improved response rates among patients that received an allogeneic cell-based treatment strategy, we specifically compared the CR rates and survival of patients treated with chemotherapy followed by any type of allogeneic cell based therapy with patients treated with intensive chemotherapy alone. The rate of CRs was significantly higher for patients treated with chemotherapy in combination with stem cell-based treatment (57% CRs) compared with patients treated with intensive chemotherapy alone (13% CRs; P = 0.002; Figure 2a) . Death due to progressive/refractory disease occurred in 79% of patients treated with chemotherapy alone compared with 55% of patients that received immune therapy. In contrast, fatal complications due to infectious complications, other reasons not related to progressive disease or treatment or GVHD, were about twice as high in the patient cohort chemotherapy plus immunologic therapy (45% vs 21%; P = 0.24) (Figure 2b) .
The probability of OS after 3 years was 0% for patients treated with chemotherapy and 16.2% (95% CI; 6.0-26.4%) for patients who received a combination of chemotherapy and immune intervention. This difference was not statistically significant (P = 0.19; Figure 2c ). However, a comparison of the two KaplanMeier curves revealed that an OS plateau of~10% could only be seen in patients who received chemotherapy and allogeneic cellbased therapy, whereas none of the patients treated with chemotherapy alone survived more than 3 years. 
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Comparing the outcome of patients with early relapse after Allo-SCT who received potentially curative treatment strategies with the ones that were treated non intensively, our analysis revealed a significantly improved OS rate for patients with intensive treatment compared with patients who received palliative treatment. The median OS was 160 days (95% CI; 133-187 days) and 63 days (95% CI; 47-79 days), respectively (P = 0.004).
Risk factors influencing response to salvage therapy and OS Time to relapse after first Allo-SCT was the most important factor, influencing response to salvage therapy in our patient cohort. Of all patients having received intensive salvage treatment, the CR rate for patients who relapsed more than 149 days (median time between SCT and relapse) after SCT was 60% compared with 30% in patients with earlier relapse (P = 0.016; Figure 3a) .
Consequently, a period of more than 149 days from first transplantation until relapse was also the only factor positively influencing OS. Median OS was 161 days (95% CI; 122-200) compared with 84 days (95% CI; 33-135 days) in patients with a shorter period of time interval from SCT to relapse (P = 0.002; Figure 3b ).
None of the other risk factors (pretreatment characteristics, disease status at the time first Allo-SCT, details of transplantation) had a significant impact on response to salvage therapy or OS in our univariate analysis (Table 4) .
A multivariate analysis with the inclusion of factors potentially influencing OS identified a period of more than 149 days from first Allo-SCT until relapse to be the only independent risk factor for OS in our patient cohort (HR 1.92; 95% CI; 1.27-2.9; P = 0.002).
DISCUSSION
Relapse after Allo-SCT remains the leading cause of treatment failure for patients with myeloid malignancies such as AML and MDS. 24, 25 So far, intensive treatment, either consisting of chemotherapy or any type of immunologic therapy or the combination of both remains the only chance of long-time disease-free survival for patients with AML or MDS relapsing after Allo-SCT. In our cohort, 70 of 108 patients (65%) received intensive treatment, which is comparable to other studies that reported rates of patients considered for aggressive treatment after relapse to be between 54 and 87%. [26] [27] [28] These results indicate that there is a significant number of patients eligible for intensive treatment even after previous allogeneic transplantation. However, despite all efforts to identify a potential curative salvage therapy, our retrospective analysis elucidate the poor response and survival rates with a median OS of 130 days and only 19% of the patients alive at 1 year after relapse. These data are in line with other patient cohorts that have been previously reported on. 17, 18, 29 Several risk factors predicting survival in patients with AML and MDS undergoing Allo-SCT have been described including age, cytogenetic and molecular genetic findings at diagnosis, remission status and general performance at the time of transplantation and the occurrence of GVHD after transplantation. [30] [31] [32] [33] These factors also influence response and survival rates of patients undergoing salvage therapy for relapse after allogeneic transplantation, but the remission duration after first allogeneic transplantation was the most significant factor to determine the outcome of AML and MDS patients with relapse after Allo-SCT in all previous published studies. 5, 16, 34 The time period between first allogeneic transplantation and relapse was also the only independent risk factor influencing OS in our multivariate analysis. Therefore, relapse-free survival after Allo-SCT should be taken into consideration whenever treatment decisions have to be made for relapsed patients with AML or MDS after transplantation. No other factor had a similar influence on patients' outcome in our cohort, which may have been caused, at least partially by the limited numbers of patients in our analysis. Figure 1 . Kaplan-Meier survival estimates for all patients with AML or high-risk MDS, who relapsed after allogeneic transplantation. Tick marks represent patients whose data were censored at the last time they were known to be alive; 95% CI = 95% confidence interval.
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Nevertheless, our data revealed that several pre-transplant factors such as Flt3-ITD mutation, NPM1 wild type, a short duration of first CR (⩽4 months), the number of chemotherapy cycles needed to achieve a first CR and active disease at the time of transplantation were associated with a higher risk for early relapse (o149 days). Most of these factors are known to be associated with outcome in AML patients receiving induction chemotherapy or Allo-SCT. [35] [36] [37] The results of our analysis elucidate a potential role of these factors in predicting outcome of patients with relapse after Allo-SCT.
Risk factors are of importance in identifying patients with relapse after Allo-SCT, who may benefit from intensive salvage therapy. Thus, the optimal treatment strategy for those patients has not yet been identified. We therefore compared outcome parameters of patients that received different salvage therapy regiments after relapse had been diagnosed. Highest response rates were seen among patients who received some type of immunological cell-based treatment, either as an induction therapy followed by transfusion of an allogeneic stem cell boost from the previous donor at the time of BM aplasia or a second Allo-SCT. Disappointingly, CR rates of up to 73% in these patients . Differences in response rates, causes of death and OS in patients treated with chemotherapy alone compared with patients who received a stem-cell-based treatment approach. (a) CR rates were significantly higher in patients who underwent a stem-cell-based therapy.
(b) Causes of death were subdivided into three groups: death due to progressive or refractory disease, death from GVHD or death due to infection or any other cause with no signs of progressive/refractory disease. Death due to disease progression happened more frequently among patients who received chemotherapy alone, whereas patients treated with chemo-and immune therapy were at a higher risk to die from infectious complications or GVHD. (c) OS did not differ significantly between the two treatment groups but according to the KaplanMeier survival estimates, long-term survivors could only be seen among patients treated with a stem-cell-based therapy (gray line).
did not translate into improved OS due to higher mortality caused by infectious complications and GVHD. Nevertheless, only patients treated with chemotherapy followed by application of allogeneic stem cells, either as a stem cell boost or a second allogeneic transplantation after myeloablative therapy, were among longterm survivors, leading to the conclusion that this regimen might be a reasonable treatment option for patients eligible for intensive therapy. Treatment with intensive chemotherapy alone was associated with increased mortality due to progress of the underlying disease and was not able to facilitate long-term survival.
Taking the above-mentioned conclusions into consideration, the application of genetically modified autologous immune effector cells may represent a promising new treatment strategy. T cells containing a chimeric Ag receptor have been used to target distinct Ags on the malignant blast cells such as CD33, 38, 39 
CD123
40 and the LeY Ag. 41 Even though the first results of this gene therapy for myeloid malignancies come from pre-clinical studies, the published response rates in lymphatic malignancies with T cells containing a chimeric Ag receptor targeting the CD19 antigen are encouraging. 42, 43 Further, cytokine-induced killer cells, a population of immune effector cells featuring a mixed T-and natural killer cell-like phenotype, have shown considerable cytotoxicity against hematological malignancies, rendering them attractive for further research in adoptive immunotherapy. 44 The Abbreviations: 95% CI = 95% confidence interval, ELN = European Leukemia Network; Flt3 = fms like tyrosine kinase 3; HCT-CI = the Hematopoietic Cell Transplant-Co-morbidity Index; MDS = myelodysplastic syndrome; MMUD = mismatched unrelated donor; MRD = matched related donor; MUD = matched unrelated donor; NPM1 = nucleophosmin 1. P-values for CR-rate-Χ 2 -test; P-values for median OS-log-rank test.
a One patient who received a haploidentical match was excluded from the risk factor analysis.
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antitumor activity of cytokine-induced killer cells is T-cell-receptor independent and is mainly attributed to the cell-cell contactdependent natural killer group 2 member D (NKG2D) cell-surface receptor. Phase I clinical studies have shown antileukemic activity of allogeneic cytokine-induced killer cells transfusion in AML patients with relapse after Allo-SCT. 45 Interestingly, in murine models, allogeneic cytokine-induced killer cells exhibited a higher antitumor toxicity, whereas signs of GVHD reactions were minimal or even not present at the same time, which would represent a clear advantage over allogeneic DLI's. 46 Larger-scaled clinical studies will have to show whether adoptive immunotherapy may have the potential to improve the outcome of patients with AML or high-risk MDS, who relapse after Allo-SCT.
As patients with relapse after Allo-SCT, who are treated with currently available treatment options, carry a poor prognosis, the prevention of disease recurrence might be the key to improve the long-term outcome of these patients. 5-azacytidine, given as a maintenance therapy, has demonstrated potential to prolong EFS and OS. 47 The detection of minimal residual disease using either flow cytometry, 48 genetic markers 49 or decreased donor cell chimerism status 50 is useful for predicting relapse. Studies, using MRD directed preemptive treatment strategies in order to prevent relapse after Allo-SCT, have produced encouraging results. 51 Furthermore, Yan et al. 52 were able to significantly improve the outcome of patients with acute leukemia by preemptive DLI application upon increasing results of minimal residual disease testing after Allo-SCT.
Taken together, the results of our analysis elucidate the poor prognosis of AML and MDS patients relapsing after allogeneic transplantation, even though the analysis has limitations that have to be taken into account. First, as it is a single-center experience, patient numbers are limited. Therefore, the influence of possible risk factors on response rates and survival may be under-or overestimated. Second, conclusions concerning the patients' treatment are restricted owing to the retrospective design of the analysis. The selection of further therapy with different intensities happened on a strictly individual basis. Thus, this patient selection has possibly influenced the final outcome of our analysis as a confounding variable with an impact on outcome comparable or even exceeding the impact of various treatment approaches.
However, it is suggestive that time from allogeneic transplantation until relapse represents a crucial factor to predict response to salvage treatment and survival in this patient cohort. Patients eligible for intensive salvage therapy should be offered a stem cell-based treatment approach, which harbors the highest chance for long-term survival.
